8-K: Bright Green Corp. Files for Chapter 11, Plans Restructuring and Shift to Controlled Substances

Bright Green Corporation has filed for Chapter 11 bankruptcy to implement a prepackaged restructuring plan, including a shift away from cannabis and towards the production of DEA scheduled controlled substances.

Summary

• Bright Green Corporation has filed for Chapter 11 bankruptcy and entered into an amended Restructuring Support Agreement (RSA) with its majority shareholder, Lynn Stockwell.
• The RSA outlines a prepackaged plan for restructuring the company, including funding of a $6.5 million Exit Facility by the Plan Sponsor, Lynn Stockwell.
• The plan includes paying administrative and professional fee claims in full, rolling up Stockwell's secured claim of $840,315 plus the value of DMAA shares into the Exit Facility, and reorganizing the company.
• General unsecured claims will be repaid with 20% cash from a mortgage on the company's property and 80% in stock held by Ms. Stockwell in Drugs Made In America Acquisition Corp. (DMAA).
• The company plans a reverse stock split at a ratio of 50-1.
• Bright Green is withdrawing all cannabis-related renewal applications with the DEA and shifting its focus to the production of DEA scheduled controlled substances.
• The company anticipates changing its name to Drugs Made In America Corp.
• The company plans to list its common stock on the NASDAQ by curing the share price deficiency and meeting all other requirements for listing.
• The company has filed a voluntary petition in the United States Bankruptcy Court for the District of New Mexico for relief under chapter 11 of the Bankruptcy Code.
• The company must obtain votes accepting the Prepackaged Plan from two-thirds of holders of general unsecured creditors in the Chapter 11 Case.

Sentiment

Score: 4

Explanation: While the company presents a positive outlook for its restructuring and new business direction, the Chapter 11 filing and associated risks temper the overall sentiment.

Positives

• The restructuring plan aims to pay all creditors with approved claims in full.
• Equity shareholders will retain their interests in the company without dilution.
• The company is shifting its focus to the production of legal controlled substances for medical purposes, establishing a reliable API supply chain.
• The company plans to list its common stock on the NASDAQ by curing the share price deficiency and meeting all other requirements for listing.
• The company believes that the timing for both revenue streams will create this opportunity and Bright Green Corporation will reset in a very positive way immediately.

Negatives

• The company has filed for Chapter 11 bankruptcy, indicating financial distress.
• Trading in the company's securities during the Chapter 11 Case is highly speculative and poses substantial risks.
• The company is withdrawing from the cannabis business, potentially abandoning previous investments and strategies.
• The company must obtain votes accepting the Prepackaged Plan from two-thirds of holders of general unsecured creditors in the Chapter 11 Case.

Risks

• Trading in the company's securities during the Chapter 11 Case is highly speculative and poses substantial risks.
• The effectiveness of the Prepackaged Plan is subject to numerous conditions, including approval by the Bankruptcy Court.
• The company's ability to meet the requirements, and compliance with the terms, including restrictive covenants, of the Restructuring Support Agreement and any other financial arrangement while in Chapter 11 proceedings.
• Changes in the company's cash needs as compared to its historical operations or its planned reductions in operating expense.
• Adverse litigation changes in domestic and international demand for the company's products.
• The company's ability to control operating costs and other expenses that general economic conditions may be worse than expected.
• Competition may increase significantly.
• Changes in laws or government regulations or policies affecting the company's current business operations.

Future Outlook

The company plans to reorganize, change its name to Drugs Made In America Corp., list its common stock on the NASDAQ, and focus on the production of DEA scheduled controlled substances, with potential revenue from contracts and EB-5 investments.

Management Comments

• Lynn Stockwell said, the Company will not canvas equity and then jeopardize shareholder value by the uncertainty of the United States Cannabis industry, currently this is not a business where normal banking is prohibited.
• Lynn Stockwell continues, this new federal administration is actively positioning Bright Green to participate in the production, drug manufacturing and prescription drug delivery back to the United States.

Industry Context

The company is shifting away from the uncertain cannabis industry and focusing on the production of legal controlled substances, aiming to establish a reliable API supply chain in the United States and reduce reliance on imports.

Comparison to Industry Standards

• The document mentions Drugs Made In America Acquisition Corp. (DMAA), a NASDAQ listed company, as part of the restructuring plan, indicating a potential comparison point for future performance.
• The company's plan to engage with 60 participant franchisees to build and manage facilities for controlled substance production is a unique approach compared to traditional pharmaceutical manufacturing models.
• The company's reliance on the EB-5 program for capital generation is a less common strategy compared to traditional funding methods in the pharmaceutical industry.

Management Changes

Legal Proceedings

• The Company also plans to file a motion on the disputed claimed by John Fikany in connection with an ongoing lawsuit against the Company in New Mexico.

Stakeholder Impact

• Shareholders face speculative trading conditions and potential risks during the Chapter 11 Case.
• Creditors are subject to the terms of the restructuring plan, with general unsecured creditors receiving a combination of cash and stock.
• Employees may experience uncertainty during the restructuring process.
• The company's shift in business focus may impact suppliers and customers in the cannabis industry.

Next Steps

• Obtain Bankruptcy Court approval for the Restructuring Support Agreement and Prepackaged Plan.
• Solicit votes from general unsecured creditors to accept the Prepackaged Plan.
• Implement the reverse stock split.
• Secure necessary governmental, regulatory, and licensing approvals for controlled substance production.
• Cure the share price deficiency and meet all other requirements for listing on the NASDAQ.
• Engage with 60 participant franchisees to build and manage facilities for controlled substance production.
• Continue partnership with Asia Capital Pioneer Group Inc to support EB-5 marketing efforts.

Key Dates